Therapeutic Outlook in DLBCL: Evaluating Treatment Sequencing from Front-line to Relapsed Refractory Disease - Episode 8
Safety Considerations for Second-line CAR T-cell Therapy in Relapsed/Refractory DLBCL
A review of studies on safety management with CAR T-cell therapy, focusing on CRS/ICANS in the relapsed/refractory setting, key takeaways from Cohorts 4 and 6, and the impact of ZUMA-24 preliminary analysis on second-line safety strategies.
Video content above is prompted by the following:
Please review studies evaluating safety management with CAR T-cell therapy use (Oluwole et al. Br J Haematol 2021; Topp et al. Br J Haematol 2021).
- Discuss CRS/ICANS associated with CAR T-cell therapy in RR setting.
- What are key takeaways from Cohorts 4 and 6 and how will that influence your practice?
- How does the preliminary analysis from ZUMA-24 impact safety management in the 2L setting (Leslie et al. EHA 2024)?
Related Content:
